9 news items
Kineta Provides Update On Its Ongoing Phase 1/2 VISTA-101 Clinical Trial And Corporate Activities; Received $500,000 Investment From An Existing Investor
KA
15 May 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
KA
15 May 24
Partial response
Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
ACB
ACORQ
ADIL
10 Apr 24
. (NASDAQ:KA) dipped 14% to $0.3699. Kineta recently reported initial clinical response data at the AACR 2024 of its ongoing Phase 1/2 VISTA
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
ACB
ACRV
AMD
9 Apr 24
. (NASDAQ:KA) fell 17.1% to $0.4490. Kineta reported initial clinical response data at the AACR 2024 of its ongoing Phase 1/2 VISTA-101 clinical trial
Kineta Reports Initial Clinical Response Data At AACR 2024 Of Ongoing Phase 1/2 VISTA-101 Clinical Trial
KA
8 Apr 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
k2uc628 6t
KA
8 Apr 24
Partial response
hj4x2uz9djsbuginlh02y6bu5l0lbmkw3v
KA
21 Mar 24
Partial response
l2kiyrzwzd0sce1nucvyxbq 3t0
KA
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
veadwlnid k0wo817acbv1ky0ppj9wsxhbcv5efj5isi0dmjigx
KA
22 Feb 24
of response to other immune checkpoint inhibitors. Blocking VISTA induces an efficient polyfunctional immune response to address immunosuppression
- Prev
- 1
- Next